Streptozotocin-Induced Diabetic Models in Mice and Rats

被引：987

作者：

Furman, Brian L. ^{[1
]}

机构：

[1] Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland

来源：

CURRENT PROTOCOLS | 2021年 / 1卷 / 04期

关键词：

high-fat; hyperglycemia; insulin deficiency; insulin resistance; insulitis; mouse or rat; nicotinamide; streptozotocin; type 1 diabetes mellitus; type 2 diabetes mellitus;

D O I：

10.1002/cpz1.78

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Streptozotocin (STZ) is an antibiotic that causes pancreatic islet beta-cell destruction and is widely used experimentally to produce a model of type 1 diabetes mellitus (T1DM). Detailed in this article are protocols for producing STZ-induced insulin deficiency and hyperglycemia in mice and rats. Also described are protocols for creating animal models for type 2 diabetes using STZ. These animals are employed for assessing the pathological consequences of diabetes and for screening potential therapies for the treatment of this condition. (c) 2021 The Authors.

引用

页数：21

共 55 条

[1]

Arison R.N., Ciaccio E.I., Glitzer M.S., Cassaro J.A., Pruss M.P., Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin, Diabetes, 16, pp. 51-56, (1967)

[2]

Bond J.S., Failla M.L., Unger D.F., Elevated manganese concentration and arginase activity in livers of streptozotocin-induced diabetic rats, Journal of Biological Chemistry, 258, pp. 8004-8009, (1983)

[3]

Bonnevie-Nielsen V., Steffes M.W., Lernmark A., A major loss in islet mass and B-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin, Diabetes, 30, pp. 424-429, (1981)

[4]

Breyer M.D., Bottinger E., Brosius F.C., Coffman T.M., Harris R.C., Heilig C.W., Mouse models of diabetic nephropathy, Journal of the American Society of Nephrology, 16, pp. 27-45, (2005)

[5]

Brondum E., Nilsson H., Aalkjaer C., Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models, Hormone and Metabolic Research, 37, pp. 56-60, (2005)

[6]

Byrne F.M., Cheetham S., Vickers S., Chapman V., Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments, Journal of Diabetes Research, 2015, (2015)

[7]

Chan P., Wong K.L., Liu I.M., Tzeng T.F., Yang T.L., Cheng J.T., Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats, Journal of Hypertension, 21, pp. 761-769, (2003)

[8]

Chao P.C., Li Y., Chang C.H., Shieh J.P., Cheng J.T., Cheng K.C., Investigation of insulin resistance in the popularly used four rat models of type-2 diabetes, Biomedicine & Pharmacotherapy, 101, pp. 155-161, (2018)

[9]

Deeds M.C., Anderson J.M., Armstrong A.S., Gastineau D.A., Hiddinga H.J., Jahangir A., Kudva Y.C., Single dose streptozotocin induced diabetes: Considerations for study design in islet transplantation models, Laboratory Animals, 45, pp. 131-140, (2011)

[10]

de Souza R.J., Mente A., Maroleanu A., Cozma A.I., Ha V., Kishibe T., Anand S.S., Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: Systematic review and meta-analysis of observational studies, BMJ, 351, (2015)

← 1 2 3 4 5 6 →